Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study

Abstract

Pharmacological inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) is an established therapeutic option to treat hypercholesterolemia, and plasma PCSK9 levels have been implicated in cardiovascular disease incidence. A number of genetic variants within the PCSK9 gene locus have been shown to modulate PCSK9 levels, but these only explain a very small percentage of the overall PCSK9 interindividual variation. Here we present data on the genetic association structure between PCSK9 levels and genom-wide genetic variation in a healthy sample from the general population. We performed a genome-wide association study of plasma PCSK9 levels in a sample of Brazilian individuals enrolled in the Estudo Longitudinal de Saude do Adulto cohort (n=810). Enrolled individuals were free from cardiovascular disease, diabetes and were not under lipid-lowering medication. Genome-wide genotyping was conducted using the Axiom_PMRA.r3 array, and imputation was performed using the TOPMED multi-ancestry sample panel as reference. Total PCSK9 plasma concentrations were determined using the Quantikine SPC900 ELISA kit. We observed two genome-wide significant loci and seven loci that reached the pre-defined value of p threshold of 1×10−6. Significant variants were near KCNA5 and KCNA1, and LINC00353. Genetic variation at the PCSK9 locus was able to explain approximately 4% of the overall interindividual variations in PCSK9 levels. Colocalization analysis using eQTL data suggested RWDD3, ATXN7L1, KCNA1, and FAM177A1 to be potential mediators of some of the observed associations. Our results suggest that PCSK9 levels may be modulated by trans genetic variation outside of the PCSK9 gene and this may have clinical implications. Understanding both environmental and genetic predictors of PCSK9 levels may help identify new targets for cardiovascular disease treatment and contribute to a better assessment of the benefits of long-term PCSK9 inhibition.

Genome-wide association study for Chagas Cardiomyopathy identify a new risk locus on chromosome 18 associated with an immune-related protein and transcriptional signature

“…Genomic DNA extraction has been previously described [ 8 ]. SaMi-Trop DNA samples were genotyped using two different genotyping arrays: Axiom_PMRA.r3 array (N = 2,606) or the Axiom_sarscov array (N = 792) (ThermoFisher, Waltham, USA) and genotypes annotated using the array specific annotation file provided at the ThermoFisher website.…”

Impact of RSUME Actions on Biomolecular Modifications in Physio-Pathological Processes

“…Similarly, the previously described GWAS study that associates an SNP affecting an RSUME’s QTL with cardioembolic stroke ( 19 ) provides a novel view for the hypoxia-mediated regulation of RSUME expression in cardiac tissue. Moreover, a different study found a suggestive locus near the RSUME gene that is involved in inter-individual levels of the Proprotein convertase subtilisin/kexin type 9 (PCSK9), which is a regulator of LDL receptor degradation and is associated with cardiovascular risk ( 45 ). Although the incidence of congenital heart defects is high, only a reduced number of them are caused by Mendelian inheritance ( 46 ).…”